Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Antisense oligonucleotide as a novel therapy for people with CF affected by the W1282X mutation

Antisense oligonucleotide as a novel therapy for people with CF affected by the W1282X mutation

Resource Type

CF Research News

Authors

Yifat S. Oren, Ofra Avizur-Barchad, Efrat Ozeri-Galai, Renana Elgrabli, Meital R. Schirelman, Tehilla Blinder, Chava D. Stampfer, Merav Ordan, Onofrio Laselva, Malena Cohen-Cymberknoh, Eitan Kerem, Christine E Bear, Batsheva Kerem

References

J Cyst Fibros. 2021 Dec 28;S1569-1993(21)02172-X. doi: 10.1016/j.jcf.2021.12.012.

Document

PDF icon CF Research News Article [1]

Link

Scientific Abstract [2]

Theme

CFTR/Basic Science [3]

Keywords

Antisense oligonucleotides [4]
drug development [5]
Exon skipping [6]

Date

Tuesday, December 28, 2021

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [7]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/antisense-oligonucleotide-novel-therapy-people-cf-affected-w1282x

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-21-00355R3_FINAL_Kerem_040222.pdf [2] https://pubmed.ncbi.nlm.nih.gov/34972649/ [3] https://www.ecfs.eu/research-article-themes/cftrbasic-science [4] https://www.ecfs.eu/research-article-keywords/antisense-oligonucleotides [5] https://www.ecfs.eu/research-article-keywords/drug-development [6] https://www.ecfs.eu/research-article-keywords/exon-skipping [7] https://www.ecfs.eu/resource-guideline-type/other-guidelines